Dwi Octamy Sari
Unknown Affiliation

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

Roflumilast: A Review of Chronic Obstructive Pulmonary Disease (COPD) Treatment Ita Octafia; Dwi Octamy Sari; Novi Wulandari; Sandra Annisa; Linda Wahyuni Wongkar; Ferdias Kurnia Bahari; Faiz Farikhah; Moh Firmansah; Erfin Midhiawati; Fauna Herawati
Qanun Medika - Jurnal Kedokteran FK UMSurabaya Vol 5, No 1 (2021)
Publisher : Universitas Muhammadiyah Surabaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30651/jqm.v5i1.5043

Abstract

Abstract Chronic Obstructive Pulmonary Disease (COPD) is a chronic airway inflammation with resulting progressive airflow limitation that has a high incidence, morbidity, and mortality. Roflumilast is an oral phosphodiesterase-4 inhibitor as a therapy to decrease the risk of COPD exacerbations in patients with moderate-severe COPD with a history of chronic bronchitis. Roflumilast can be given orally once daily as a single or combination drug. It can be used as COPD moderate-severe but also more beneficial as COPD mild treatment. The efficacy of Roflumilast can prevent exacerbations of repetition and can fixed lung function both in terms of FEV1 and vital capacity to force. The incidence of side effects, which are diarrhea and digestive disorders. The cost-effectiveness showed that Quality of life patient with Roflumilast is better than the group without additional. This paper aimed to review systematically Roflumilast as COPD treatment for the clinical application.Keywords                   : COPD, Roflumilast, phosphodiesterase-4 inhibitorCorrespondence          : fauna@staff.ubaya.ac.id